Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Retrophin
Biotech
FDA sets back Travere's plans for kidney disease drug approval
The FDA has crushed Travere Therapeutics’ hopes of seeking accelerated approval in a rare kidney disorder on the strength of existing interim data.
Nick Paul Taylor
May 26, 2021 8:10am
Retrophin sheds Shkreli connection with new name: Travere
Nov 17, 2020 10:30am
Retrophin buys up Orphan Technologies for rare disease drug
Oct 23, 2020 8:18am
Disarm Therapeutics brings on former Enzyvant boss as CEO
Jul 22, 2019 11:08am
From prison, Shkreli sues—and settles with—Retrophin executives
Jun 21, 2019 10:33am
Chutes & Ladders—Cell Medica names Kite's European chief as CEO
Aug 3, 2018 9:43am
